Illimis Therapeutics
Agent36Agent Readiness: 36/100. Below median. Measured by StartupHub.ai. Median 41.Trust65Data Trust: 65/100. Above median. Measured by StartupHub.ai. Median 61.Develops novel biologics for neurodegenerative diseases.
About
Illimis Therapeutics is a biotechnology company focused on translating cutting-edge science into innovative medicines for intractable diseases. Their core efforts include developing treatments for Alzheimer's disease, such as their GAIA-Aβ program aimed at overcoming limitations of existing therapies by addressing ARIA. They serve patients and their families suffering from debilitating conditions by striving to improve their quality of life through sustainable innovation.
Key facts
- Website
- illimistx.com
- Headquarters
- Seoul, South Korea
- Founded
- 2021
Tech stack
Detected on illimistx.com, last scanned 18 Oct 2026. Run your own scan
- Frontend
- jQuery
- Backend
- PHP
- Analytics
- Google Analytics 4
- Email provider
- Microsoft 365
Illimis Therapeutics scores 4. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Illimis Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Illimis Therapeutics is 65 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Illimis Therapeutics
